CRISPR Therapeutics’ chief operating officer, Julianne Bruno, will be stepping down from the company to “pursue external opportunities,” revealed CRISPR in a brief press statement.
Bruno’s departure is effective as of April 11, 2025. She has been with CRISPR since April 2019, taking on the COO role in May 2024, following a promotion from senior VP and head of programs & portfolio management.
The company has had its fair share of executive churn. In 2017, Rodger Novak, M.D., co-founder and CEO stepped down from his role for personal reasons, and was replaced by current CEO Samarth Kulkarni, Ph.D. In September 2023, Novak resigned as president and chairman, leaving the company entirely. In December 2023, six days after CRISPR received its historic approval for its gene therapy, Casgevy, in patients with sickle cell disease, the company’s chief medical officer, Dr. Phuong Khanh Morrow, resigned.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!